Invion Ltd. · ASX:IVX
Invion — Investor Presentation (June 2025)
29 slides from Invion's investor presentation, Jun 4, 2025
Slide 1: ASX Announcement: Investor Presentation
ASX ANNOUNCEMENT INVESTOR PRESENTATION MELBOURNE (AUSTRALIA) 04 June 2025: Invion Limited (ASX: IVX) (“Invion” or the “Company”) wishes to release the attached presentation, which will be used by the Company’s Executive Chair and Chief Executive Officer, Thian Chew, at various investor meetings and
Slide 2: Corporate Presentation June 2025
For personal use only CORPORATE PRESENTATION June 2025 Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases ASX: IVX
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Company Highlights
COMPANY HIGHLIGHTS INVION AT CLINICAL INFLEXION POINT ACROSS MULTIPLE CANCERS Clinical Results: Multiple Cancers For personal use only Successful Ph II prostate cancer trial results, ongoing Ph I/II skin cancer trial and upcoming anogenital cancer trial Key Advantages Selectively targets cancer cell
Slide 5: Year of Achievements
YEAR OF ACHIEVEMENTS CONTINUED PROGRESS ON KEY CLINICAL MILESTONES For personal use only Results Ph I/II Skin Cancer Achievements in 2024 Clinical Trial ✓ Successful Ph 2 Prostate Cancer Clinical Trial Results Initiation Ph I/II Anogenital ✓ Patient Recruitment for Ph I/II Skin Clinical Trial with P
Slide 6: The Photosoft Advantage
THE PHOTOSOFTTM ADVANTAGE NEXT GENERATION IMPROVEMENT ON APPROVED PDTs There are several approved PDT treatments on For personal use only Photosoft is a minimally invasive modality for the market, but Photosoft is a ground- treating cancer that specifically identifies and breaking technology that ov
Slide 7: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS, ATTRACTIVE THERAPEUTIC PROFILE For personal use only IVX Photosensitiser for Cancer: INV043 Effective in regressing multiple types of cancer in human trials and in vivo1 PhotosoftTM Potency: ~600x greater photoxicity than Talaporfin (widely used ph
Slide 8: Results and Findings: Cancer
For personal use only RESULTS AND FINDINGS: CANCER
Slide 9: Phase II Prostate Cancer Clinical Trial
PHASE II PROSTATE CANCER CLINICAL TRIAL INVESTIGATOR-LED PROSTATE CANCER STUDY USING INV043* For personal use only Screening: Men between 50-80 years with 1st cohort of COVID-19 Lockdowns: 10 patients ▪ Biopsy proven primary prostate cancer, or dropped out. Remaining treated 25 patients but with inc
Slide 10: Phase II Prostate Trial Results: Sublingual (Systemic)
PHASE II PROSTATE TRIAL RESULTS: SUBLINGUAL (SYSTEMIC) COMPELLING SAFETY, SOLID EFFICACY SIGNALS SAFE AND WELL TOLERATED EFFICACY: 40-44% RESPONSE RATE For personal use only When administered sublingually to patients over 6 cycles of PSMA-PET1 Results PDT treatments (from 2nd cohort, n=16) over 3 mo
Slide 11: Why Skin Cancer?
WHY SKIN CANCER? ATTRACTIVE CLINICAL TRIAL INDICATION For personal use only Relatively Cost Effective Costs to undertake skin cancer trials typically lower than for other routes of administration (e.g., intravenous) Faster Path to Market Trials with topical treatments often quicker to complete due t
Slide 12: Phase I/II Non-Melanoma Skin Cancer Trial
PHASE I/II NON-MELANOMA SKIN CANCER TRIAL SAFETY REVIEW COMMITTEE FINDINGS – INITIAL PATIENT GROUP Change in size of NMSC lesions Findings from Safety Review Committee (SRC) For personal use only treated and untreated lesions* (initial patient group of 6) ▪ No adverse events identified related to th
Slide 13: Evaluation of NMSC Therapies
EVALUATION OF NMSC THERAPIES1 POTENTIAL TO DISPLACE STANDARD OF CARE Non-Melanoma Skin Cancer (NMSC) Phase I/II Clinical Trial (Adaptive Trial Structure): Addressing the unmet need for one of the world’s most common cancers2 For personal use only GOOD INV043 (Topical) Metvix#/ALA PDT Treatment #by G
Slide 14: INV043 Fluoresces Cancers Under Violet Light
INV043 FLUORESCES CANCERS UNDER VIOLET LIGHT DIAGNOSTIC POTENTIAL Potential for INV043 to assist surgeons to more accurately remove cancers For personal use only Animal studies at Hudson Institute Patient 101-002 from Ph I/II NMSC Trial: Day 1 of the treatment • Primary pancreatic (Human PANC1) canc
Slide 15: Theragnostic Potential
THERAGNOSTIC POTENTIAL MULTIPLE CANCERS, PRECISION CANCER TARGETING, PROTECTIVE IMMUNITY SELECTIVE TARGETING PROTECTIVE IMMUNITY For personal use only Control Treated https://inviongroup.com/videos-reports/ • INV043 selectively retained in malignant but not healthy • Triple Negative Breast Cancer (T
Slide 16: Combination with Immune Checkpoint Inhibitors (ICI)
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL • Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as
Slide 17: Target Indications and Timeframes
TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA (CALENDAR YEAR) 1H2024 2H2024 1H2025 2H2025 >CY26 For personal use only CANCER1 Prostate Cancer (Funded by RMWC) Completed Follow up and monitoring Non-Melanoma Skin Cancers (Topical)2 Adaptive study design Anoge
Slide 18: Creating Impact for Treating Cancers Globally
CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Commercial Rationale for Photosoft For personal use only Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, Works across multiple cancers without need making affordability even to personalise
Slide 19: Infectious Diseases
For personal use only INFECTIOUS DISEASES Commercialisable Pipeline
Slide 20: Broad-Spectrum Anti-Microbial Potential
BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL ANTI-MICROBIAL TREATMENTS – WITHOUT RESISTANCE “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” For personal use only World Health Organisation1 Leading Institutions: Viroclinics conducted virus SARS-CoV-2: Omicron tests & ACARE (U
Slide 21: Target Antimicrobial Indications
TARGET ANTIMICROBIAL INDICATIONS COST EFFECTIVE AND ACCELERATED PATHS TO CLINICAL TRIALS HPV PROGRAM FUNDED BY DR.INB PERIODONTAL DISEASE For personal use only HPV distribution profile in women 1 57.7% 44.4% 42.2% 21.4% 3.7% Eastern Asia Central & Sub-Saharan Eastern Western Southern Africa Europe E
Slide 22: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS PROF THIAN CHEW PROF ROBERT RAMSAY EXECUTIVE CHAIRMAN & CEO SCIENTIFIC ADVISOR For personal use only • Co-Founder, Chronic Airway Therapeutics • 30+ years research in cancer biology &translational medicine • Advisory Board, Stanford Medicine CARE • Se
Slide 23: For personal use only
For personal use only For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 M: +61 409 341 613 E: investor@inviongroup.com E: brendon.lau@inviongroup.com
Slide 24: Appendices
For personal use only APPENDICES
Slide 25: The Photosoft Advantage
THE PHOTOSOFTTM ADVANTAGE NEXT GENERATION IMPROVEMENT ON APPROVED PDTs For personal use only 24
Slide 26: Target Diseases and Indications
TARGET DISEASES AND INDICATIONS PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES* PRIMARY FOCUS: CANCER (INV043) INFECTIOUS DISEASES For personal use only ▪ Multiple cancer indications ▪ Broad spectrum antimicrobial activity ▪ Ablation and activation of immune response against viruses, bacteria
Slide 27: Treatment Options: Flexibility for Clinicians
TREATMENT OPTIONS: FLEXIBILITY FOR CLINICIANS MULTIPLE PATHWAYS FOR DRUG AND TARGETED LIGHT DELIVERY INV043 can be administered to multiple target indications via different drug and light delivery options For personal use only ROUTES OF DRUG ADMINISTRATION LIGHT ADMINISTRATION OPTIONS MULTIPLE POTEN
Slide 28: Ongoing Phase I/II Trial: Non-Melanoma Skin Cancer
ONGOING PHASE I/II TRIAL: NON-MELANOMA SKIN CANCER THERAGNOSTIC ENDPOINTS • Adaptive: Open label adaptive trial design (3+3 light dose / dose light interval escalation1) enables For personal use only flexibility in size and timing, with option for repeat treatment depending on response • Safety, Dos
Slide 29: Future Additional Indications
FUTURE ADDITIONAL INDICATIONS ADDRESSING UNMET NEEDS OF ASIAN-CENTRIC CANCERS, A US$40B MARKET5 Asians comprise 6% of clinical trial patients in For personal use only FDA approved drugs2 … yet 60% of the world is Asian UNDER-REPRESENTATION IN DRUG DEVELOPMENT MISMATCH WITH GLOBAL INCIDENCE Ethnic Br